Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Fesoterodine ER Tablets (Zwickau vs Freiburg)
NCT04478357Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fesoterodine in neurogenic detrusor overactivity (NDO) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve from Zero to Infinity at 48 hours. Started Nov 2019; status: completed.
02
Drugs
fesoterodine
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT04478357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478357.